Stereoselective glucuronidation of propranolol in human and cynomolgus monkey liver microsomes: Role of human hepatic UDP-glucuronosyltransferase isoforms, UGT1A9, UGT2B4 and UGT2B7

Pharmacology

Volumn 82, Issue 4, 2008, Pages 293-303

  Hanioka, Nobumitsu ^a   Hayashi, Keiko ^a   Shimizudani, Takeshi ^a   Nagaoka, Kenjiro ^a   Koeda, Akiko ^b   Naito, Shinsaku ^c   Narimatsu, Shizuo ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b N   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cynomolgus monkey liver microsomes; Human liver microsomes; Propranolol; Stereoselective glucuronidation; UDP glucuronosyltransferase

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; ISOENZYME; LIVER ENZYME; PROPRANOLOL; URIDINE DIPHOSPHATE;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG METABOLISM; ENANTIOMER; ENZYME KINETICS; FEMALE; GLUCURONIDATION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STEREOCHEMISTRY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANIMALS; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; MACACA FASCICULARIS; MALE; MICROSOMES, LIVER; MIDDLE AGED; PROPRANOLOL; SPECIES SPECIFICITY; STEREOISOMERISM; YOUNG ADULT;

EID: 53949125123     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000165100     Document Type: Article

References (32)

1. Barrett AM, Cullum VA: The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br J Pharmacol 1968;34:43-55.
2. Silber B, Riegelman S: Stereospecific assay for (-)- and (+)-propranolol in human and dog plasma. J Pharmacol Exp Ther 1980;215:643-648.
3. Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S: Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes: the role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 1994;22:909-915.
4. Li X, Zeng S: Stereoselective propranolol metabolism in two drug-induced rat hepatic microsomes. World J Gastroenterol 2000;6:74-78.
5. Mehvar R, Brocks DR: Stereospecific pharmacokinetics and pharmacodynamics of β-adrenergic blockers in humans. J Pharm Pharm Sci 2001;4:185-200.
6. Marathe PH, Shen DD, Nelson WL: Metabolic kinetics of pseudoracemic propranolol in human liver microsomes: enantioselectivity and quinidine inhibition. Drug Metab Dispos 1994;22:237-247.
7. Walle T: Stereochemistry of the in vivo disposition and metabolism of propranolol in dog and man using deuterium-labeled pseudoracemates. Drug Metab Dispos 1985;13:279-282.
8. Nelson WL, Shetty HU: Stereoselective oxidative metabolism of propranolol in the microsomal fraction from rat and human liver: use of deuterium labeling and pseudoracemic mixtures. Drug Metab Dispos 1986;14:506-508.
9. Silber B, Holford NH, Riegelman S: Stereoselective disposition and glucuronidation of propranolol in human. J Pharm Sci 1982;71:699-704.
10. Walle T, Walle UK, Olanoff LS: Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos 1985;13:204-209.
11. Luan LJ, Shao Q, Ma JY, Zeng S: Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects. World J Gastroenterol 2005;11:1822-1824.
12. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA: Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:72-79.
13. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T: Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers: N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 1995;39:421-431.
14. Coffman BL, King CD, Rios GR, Tephly TR: The glucuronidation of opioids, other xenobiotics, and androgens by human UGT-2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998;26:73-77.
15. Li X, Yu YN, Zhu GJ, Qian YL: Cloning of UGT1A9 cDNA from liver tissues and its expression in CHL cells. World J Gastroenterol 2001;7:841-845.
16. Sten T, Qvisen S, Uutela P, Luukkanen L, Kostiainen R, Finel M: Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10. Drug Metab Dispos 2006;34:1488-1494.
17. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, Lancet D, Louisot P, Magdalou J, Chowdhury JR, Ritter JK, Schachter H, Tephly TR, Tipton KF, Nebert DW: The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997;7:255-269.
18. Tukey RH, Strassburg CP: Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;40:581-616.
19. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW: Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005;15:677-685.
20. Hanioka N, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M: In vitro metabolism of chlorotriazines: characterization of simazine, atrazine, and propazine metabolism using liver microsomes from rats treated with various cytochrome P450 inducers. Toxicol Appl Pharmacol 1999;156:195-205.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
22. Ohno A, Saito Y, Hanioka N, Jinno H, Saeki M, Ando M, Ozawa S, Sawada J: Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol. Drug Metab Dispos 2004;32:235-239.
23. Pillot T, Ouzzine M, Fournel-Gigleux S, Lafaurie C, Radominska A, Burchell B, Siest G, Magdalou J: Glucuronidation of hyodeoxycholic acid in human liver: evidence for a selective role of UDP-glucuronosyltransferase 2B4. J Biol Chem 1993;268:25636-25642.
24. Le Guellec C, Lacarelle B, Villard PH, Point H, Catalin J, Durand A: Glucuronidation of propofol in microsomal fractions from various tissues and species including humans: effect of different drugs. Anesth Analg 1995;81:855-861.
25. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, Greenblatt DJ: Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 2003;31:1125-1133.
26. Ritter JK: Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 2000;129:171-193.
27. Strassburg CP, Oldhafer K, Manns MP, Tukey RH: Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 1997;52:212-220.
28. Ebner T, Burchell B: Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 1993;21:50-55.
29. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN: Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999;36:439-452.
30. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI: Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999;31:817-899.
31. Mackenzie PI, Little JM, Radominska-Pandya A: Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7. Biochem Pharmacol 2003;65:417-421.
32. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, Bélanger A: 3′-Azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000;28:497-502.